GlassScriptPhysician profile
Brian Stephen Postma
NPI 1114134061
$717.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $103 · 2021: $270 · 2022: $80.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $203.07 | 2019-2022 | |
| Pfizer INC. | $110.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.48 | 2020-2021 | |
| Cranial Technologies, INC | $65.77 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $63.69 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $52.80 | 2021-2022 | |
| Shire North American Group INC | $40.59 | 2019 | |
| Glaxosmithkline, LLC. | $34.54 | 2019-2022 | |
| Corium, LLC | $20.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.39 | 2021 | |
| Neos Therapeutics, LP | $19.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Postma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.